AgomAb is a biopharmaceutical company focused on the development of antibody-based therapies that modulate regenerative pathways to treat severe diseases.

Hans De Haard

Federica Linty

Manuela Cazzanti

Michael Saunders

Virginia Morello

AgomAb

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Agomab

This is a fantastic opportunity to join a small team, work on transformative science, and take part in building an exciting, science-driven global company. We are on the lookout for a Corporate Counsel.

#vacancy #corporatecounsel

We are on the lookout for an experienced Senior Data Manager to expand our clinical team. Are you ready to play a critical role in overseeing the management of clinical data? Please check our vacancy.

#clinicaldata #vacancy #clinicaltrials

We will be moving to a new building in Antwerp. The reconstruction is ongoing and it will be great!

#talent #growth #Antwerp #Biotech

In our exciting next steps to take we are looking for a Head of RA who will be responsible for developing and driving the execution of the global regulatory strategies. Are you open for a fantastic opportunity to work on transformative science in a senior ambitious team? Please check our vacancy.

#Regulatory #submission

We’re on the lookout for the spider in the web for our Clinical Operations team. If you want to give general administrative support to make sure that the team can do their work efficiently. And you have a background in trial documentation, don't hesitate please check our vacancy.

#clinicaljobs

We are on the lookout for an energized Senior Manager External Engagement with a solid medical affairs and operational background, eager to build our investigator network, partner with patient associations and take on medical communications in support of our development programs. A key role in spreading Agomab’s ambition to change patient’s live. Please check our vacancy.
#patientengagement #clinicaltrials #medicalaffairs

It is great to be back at #JPM24, where our CEO Tim Knotnerus is pleased to present the latest developments in our programs.

We have dosed the first subject in our Phase 1 #ClinicalTrial evaluating AGMB-447 as a novel treatment option for patients with Idiopathic Pulmonary Fibrosis (IPF). AGMB-447 is an inhaled lung-restricted small molecule inhibitor targeting ALK5 that has the potential to safely block TGF-beta signaling, a known master regulator of fibrosis in IPF.
To learn more about the program and the clinical trial, read the press release here on our website: https://www.agomab.com

We are thrilled to announce that our colleague Natalie de Jonge is nominated for the TOPX Females to Follow Award in the category Rising star in Industry 2024. Natalie played an important role in the Phase 2 clinical study IND/CTA approvals for AGMB-129 program in the US, Canada and EU as well as the Fast Track designation for AGMB-129 in Fibrostenosing Crohn’s Disease. Besides her professional leadership, she has been a great team player and wonderful person. Please join us in voting for this rising star! https://lnkd.in/g79sCxXj

Topx Network

Metric
Company Name	AgomAb	LégiaPark
Symbol
MSH ID	COM:AGOMAB	BE:LEGIAPARK
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Commercial & Professional Services
Industry	Biotechnology	Life Sciences
Country	BE	BE
Stage	Series D
Employee Count	49
Website	agomab.com	legiapark.be
LinkedIn	agomab	l%C3%A9giapark
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	3.02K
Web Traffic Growth	4.44
Valuation
Raised Capital	88.83M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AGOMAB

AgomAb

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue